LIMN
NASDAQLiminatus Pharma
$1.45
-0.39 (-21.20%)
2026-02-09 00:00
Healthcare
Biotechnology
--
--
Market Cap
$145.2M
P/E Ratio
N/A
52W Low
52W High
$0.54
$2.83
Volume
75.0M
About Liminatus Pharma
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Website
liminatuspharma.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2024 | N/A% | |||
| 2023 | N/A% | |||
| 2022 | N/A% | |||
| 2021 | N/A% |